Beam Therapeutics BEAM Derivative Gain Loss On Derivative Net
Derivative Gain Loss On Derivative Net at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's derivative gain loss on derivative net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's derivative gain loss on derivative net?
- Beam Therapeutics (BEAM) reported derivative gain loss on derivative net of $2.5M in Q1 2026.
- How has Beam Therapeutics's derivative gain loss on derivative net changed year-over-year?
- Beam Therapeutics's derivative gain loss on derivative net decreased by 21.9% year-over-year, from $3.2M to $2.5M.
- What is the long-term trend for Beam Therapeutics's derivative gain loss on derivative net?
- Over 3 years (2021 to 2025), Beam Therapeutics's derivative gain loss on derivative net has grown at a 17.9% compound annual growth rate (CAGR), from -$1M to $1.64M.
- What does derivative gain loss on derivative net mean?
- Represents the net realized and unrealized gains or losses resulting from derivative financial instruments used for hedging or speculative purposes. This metric highlights the volatility impact of financial risk management activities on the company's bottom line. It is critical for assessing the effectiveness of the company's hedging strategies against market fluctuations.